GlassScriptPhysician profile
Chaoyang Li
NPI 1376589515
$4,203.25
in general payments reported to CMS, 2019-2025
27 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $75.45 · 2021: $161 · 2022: $1,148 · 2023: $359 · 2024: $320 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163 · Consulting Fee: $860 · Education: $31.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.91 |
| Consulting Fee | $860.00 |
| Education | $31.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,166.85 | 2019-2022 | |
| Incyte Corporation | $892.77 | 2019-2025 | Zynyz, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $431.55 | 2019-2025 | Enhertu, Calquence |
| Beigene USA, INC. | $360.82 | 2023-2024 | Brukinsa |
| Amgen INC. | $197.28 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.13 | 2019-2021 | |
| Genentech USA, INC. | $165.86 | 2019 | |
| Rigel Pharmaceuticals, INC. | $130.80 | 2024 | Tavalisse, Rezlidhia |
| Agios Pharmaceuticals, INC. | $107.99 | 2019 | |
| Merck Sharp & Dohme LLC | $83.49 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $72.81 | 2019 | |
| Eisai INC. | $56.01 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $48.64 | 2019-2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $45.31 | 2019-2023 | Imbruvica |
| Pfizer INC. | $43.62 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $40.09 | 2019-2025 | Reblozyl |
| Astellas Pharma US INC | $30.80 | 2025 | Vyloy |
| Aveo Pharmaceuticals, INC. | $30.28 | 2025 | |
| Janssen Biotech, INC. | $18.33 | 2025 | Darzalex, Talvey, Tecvayli |
| Stemline Therapeutics INC. | $15.50 | 2025 | Orserdu |
| Tersera Therapeutics LLC | $15.24 | 2025 | Zoladex |
| Tesaro, INC. | $14.29 | 2019 | |
| Kyowa Kirin, INC. | $14.06 | 2025 | |
| Amag Pharmaceuticals, INC. | $12.94 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Clovis Oncology, INC. | $8.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaoyang Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.